Literature DB >> 10807691

Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers.

I De Vivo1, D M Gertig, S Nagase, S E Hankinson, R O'Brien, F E Speizer, R Parsons, D J Hunter.   

Abstract

Germline mutations in PTEN can predispose people to Cowden syndrome (CS) and Bannayan-Ruvalcaba-Riley (BRR) syndrome, rare, autosomal dominantly inherited neoplastic disorders. To determine whether germline mutations in PTEN contribute to genetic predisposition to multiple primary tumours within the general population, we conducted a nested case-control study, among 32 826 members of the prospective Nurses' Health Study cohort; cases were women with more than one primary tumour at different anatomical sites. We screened all nine exons of PTEN and flanking intronic splice sites for all 103 eligible cases using SSCP and sequencing. We observed two novel germline heterozygous missense mutations in exon 5 in five of the cases; three were V119L and two were V158L. Neither mutation was observed in 115 controls free of diagnosed cancer (p = 0.02). Both mutants showed partial tumour suppressor activity when compared to wild type PTEN when transfected into a PTEN null breast cancer cell line. The phenotype was cell line specific suggesting that genetic background affects growth suppression activity of the mutants. These data provide evidence that germline mutations in PTEN may be a more frequent predisposing factor for cancers in women than previously suggested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807691      PMCID: PMC1734596          DOI: 10.1136/jmg.37.5.336

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  33 in total

1.  Database of homology-derived protein structures and the structural meaning of sequence alignment.

Authors:  C Sander; R Schneider
Journal:  Proteins       Date:  1991

2.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

Authors:  D J Marsh; P L Dahia; Z Zheng; D Liaw; R Parsons; R J Gorlin; C Eng
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

4.  The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene.

Authors:  J Li; L Simpson; M Takahashi; C Miliaresis; M P Myers; N Tonks; R Parsons
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

5.  Breast cancer genes--what are the real risks?

Authors:  D Easton
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

6.  TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

Authors:  D M Li; H Sun
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

7.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

8.  Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations.

Authors:  M R Nelen; H Kremer; I B Konings; F Schoute; A J van Essen; R Koch; C G Woods; J P Fryns; B Hamel; L H Hoefsloot; E A Peeters; G W Padberg
Journal:  Eur J Hum Genet       Date:  1999-04       Impact factor: 4.246

9.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

10.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

View more
  10 in total

Review 1.  Clinical management of hereditary breast cancer syndromes.

Authors:  Amy S Clark; Susan M Domchek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-01       Impact factor: 2.673

2.  The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma.

Authors:  X-W Wan; M Jiang; H-F Cao; Y-Q He; S-Q Liu; X-H Qiu; M-C Wu; H-Y Wang
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

Review 3.  Protean PTEN: form and function.

Authors:  Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

Review 4.  Cowden syndrome: a critical review of the clinical literature.

Authors:  Robert Pilarski
Journal:  J Genet Couns       Date:  2008-10-30       Impact factor: 2.537

5.  A clinical and genetic analysis of multiple primary cancer referrals to genetics services.

Authors:  James Whitworth; Jon Hoffman; Cyril Chapman; Kai Ren Ong; Fiona Lalloo; D Gareth Evans; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2014-09-24       Impact factor: 4.246

6.  Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.

Authors:  William H Goodson; Maria Gloria Luciani; S Aejaz Sayeed; Ian M Jaffee; Dan H Moore; Shanaz H Dairkee
Journal:  Carcinogenesis       Date:  2011-09-01       Impact factor: 4.944

7.  Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England.

Authors:  H S Evans; C M Lewis; D Robinson; C M Bell; H Møller; S V Hodgson
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

Review 8.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

9.  FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.

Authors:  Oscar Maiques; Dolors Cuevas; Diego Andrés García Dios; Lieve Coenegrachts; Maria Santacana; Ana Velasco; Marta Romero; Gatius Sónia; Diether Lambrechts; Xavier Dolcet; Frederic Amant; Xavier Matias-Guiu
Journal:  Histopathology       Date:  2014-09       Impact factor: 5.087

10.  Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.

Authors:  Laura Spinelli; Fiona M Black; Jonathan N Berg; Britta J Eickholt; Nicholas R Leslie
Journal:  J Med Genet       Date:  2014-12-19       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.